Neophyr (Nitric Oxide)

Nitric oxide released from Neophyr diffuses into the pulmonary vasculature and activates soluble guanylate cyclase within smooth‑muscle cells. This activation raises cyclic GMP levels, causing smooth‑muscle relaxation and selective dilation of pulmonary vessels, which lowers pulmonary artery pressure and enhances gas exchange.

The dose of Neophyr is individualized and determined by the prescribing clinician based on the patient’s age, weight, severity of disease, and response to therapy. Administration is typically titrated to achieve a target pulmonary arterial pressure while monitoring for side effects.

Safety data for Neophyr in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Neophyr, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Neophyr delivers nitric oxide directly to the lungs, offering rapid and selective pulmonary vasodilation with minimal systemic effects. Compared with oral agents such as phosphodiesterase‑5 inhibitors or prostacyclin analogues, inhaled nitric oxide provides immediate titratable control but requires specialized delivery equipment and monitoring.

Neophyr cylinders should be stored at temperatures below 25 °C, in a well‑ventilated area, away from direct sunlight and heat sources. Keep the cylinders in their original packaging, ensure the valve is closed when not in use, and follow local regulations for medical gas handling.

Neophyr is administered by inhalation using a calibrated delivery system that mixes the gas with the patient’s inspired air. The device allows precise control of nitric oxide concentration, and administration is typically performed in a monitored clinical setting such as an intensive care unit or neonatal unit.

The most serious adverse events include severe hypotension, which can compromise systemic perfusion, and methemoglobinemia, a condition that reduces the blood’s ability to carry oxygen. Additionally, rare allergic reactions such as anaphylaxis may occur and require immediate medical attention.

Neophyr is contraindicated in patients with known methemoglobinemia, severe systemic hypotension, or hypersensitivity to nitric oxide. Caution is also advised for individuals with significant renal impairment or those receiving other potent vasodilators, as additive effects may increase the risk of low blood pressure.